Table 3.
Odds ratios (ORs) and 95% confidence intervals (CIs) of prostate cancer by season and batch-specific quartile of plasma 25(OH)D by time from blood collection to diagnosis*
| Outcome | Quartile of plasma 25(OH)D |
Ptrend† | |||||||
| Q1 |
Q2 |
Q3 |
Q4 |
||||||
| No. of case patients/No. of control subjects | OR (95% CI) | No. of case patients/No. of control subjects | OR (95% CI) | No. of case patients/No. of control subjects | OR (95% CI) | No. of case patients/No. of control subjects | OR (95% CI) | ||
| Lethal prostate cancer | |||||||||
| ≥2 y since blood collection | 29/325 | 1.00 (referent) | 24/338 | 0.82 (0.46 to 1.46) | 17/333 | 0.57 (0.30 to 1.07) | 13/335 | 0.41 (0.21 to 0.82) | .006 |
| <5 y since blood collection | 24/325 | 1.00 (referent) | 27/338 | 1.08 (0.59 to 1.99) | 14/333 | 0.59 (0.29 to 1.20) | 14/335 | 0.53 (0.26 to 1.08) | .03 |
| ≥5 y since blood collection | 15/325 | 1.00 (referent) | 8/338 | 0.50 (0.20 to 1.22) | 7/333 | 0.43 (0.17 to 1.09) | 5/335 | 0.32 (0.11 to 0.92) | .02 |
| Overall prostate cancer | |||||||||
| ≥2 y since blood collection | 258/325 | 1.00 (referent) | 245/338 | 0.91 (0.72 to 1.16) | 280/333 | 1.03 (0.82 to 1.30) | 269/335 | 1.02 (0.81 to 1.30) | .61 |
| <5 y since blood collection | 140/325 | 1.00 (referent) | 142/338 | 0.97 (0.71 to 1.33) | 139/333 | 1.04 (0.76 to 1.42) | 183/335 | 1.23 (0.91 to 1.67) | .14 |
| ≥5 y since blood collection | 167/325 | 1.00 (referent) | 158/338 | 0.87 (0.65 to 1.17) | 176/333 | 1.00 (0.74 to 1.33) | 155/335 | 0.92 (0.69 to 1.25) | .83 |
| Advanced stage at diagnosis | |||||||||
| ≥2 y since blood collection | 38/325 | 1.00 (referent) | 32/338 | 0.87 (0.53 to 1.44) | 24/333 | 0.61 (0.36 to 1.05) | 31/335 | 0.83 (0.50 to 1.38) | .27 |
| <5 y since blood collection | 27/325 | 1.00 (referent) | 27/338 | 1.05 (0.58 to 1.90) | 14/333 | 0.51 (0.25 to 1.02) | 25/335 | 0.85 (0.46 to 1.56) | .27 |
| ≥5 y since blood collection | 23/325 | 1.00 (referent) | 17/338 | 0.72 (0.37 to 1.42) | 18/333 | 0.81 (0.42 to 1.56) | 15/335 | 0.72 (0.36 to 1.45) | .42 |
| High-grade prostate cancer | |||||||||
| ≥2 y since blood collection | 54/325 | 1.00 (referent) | 47/338 | 0.83 (0.54 to 1.26) | 41/333 | 0.72 (0.46 to 1.12) | 51/335 | 0.91 (0.60 to 1.39) | .55 |
| <5 y since blood collection | 41/325 | 1.00 (referent) | 24/338 | 0.58 (0.33 to 1.01) | 24/333 | 0.57 (0.33 to 0.99) | 33/335 | 0.73 (0.44 to 1.22) | .23 |
| ≥5 y since blood collection | 28/325 | 1.00 (referent) | 31/338 | 1.01 (0.58 to 1.77) | 26/333 | 0.87 (0.48 to 1.55) | 32/335 | 1.21 (0.69 to 2.11) | .64 |
*
Adjusted for matching factors as in model 1 from previous table.
†
P values for trend were calculated using unconditional logistic regression using an ordinal variable with values of 1–4 corresponding to the quartile of plasma 25(OH)D and were two-sided.